D. E. Shaw & Co., Inc. - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$73,237
-93.4%
10,403
-92.2%
0.00%
-100.0%
Q1 2023$1,115,250
-81.8%
133,723
-74.9%
0.00%
-85.7%
Q4 2022$6,121,744
-2.0%
533,253
+7.6%
0.01%0.0%
Q3 2022$6,244,000
-26.0%
495,539
-4.5%
0.01%
-12.5%
Q1 2022$8,440,000
-46.2%
519,050
-54.2%
0.01%
-38.5%
Q4 2021$15,682,000
+12.2%
1,132,265
+16.4%
0.01%0.0%
Q3 2021$13,975,000
+1.3%
972,534
+11.5%
0.01%
+8.3%
Q2 2021$13,795,000
+2132.2%
872,526
+1335.0%
0.01%
+1100.0%
Q1 2021$618,000
+90.2%
60,803
+39.3%
0.00%
Q4 2020$325,000
+345.2%
43,640
+18.8%
0.00%
Q1 2020$73,000
-98.8%
36,720
-97.9%
0.00%
-100.0%
Q4 2019$6,068,000
+27.8%
1,758,840
+6.1%
0.01%
+16.7%
Q3 2019$4,749,000
-16.0%
1,657,379
+11.1%
0.01%
-14.3%
Q2 2019$5,652,000
-48.1%
1,491,354
+11.4%
0.01%
-50.0%
Q1 2019$10,897,000
-9.9%
1,338,695
-10.7%
0.01%
-17.6%
Q4 2018$12,101,000
-7.2%
1,499,482
-12.2%
0.02%
+6.2%
Q3 2018$13,035,000
+39.2%
1,708,319
+4.6%
0.02%
+33.3%
Q2 2018$9,362,000
+103.5%
1,633,872
+69.4%
0.01%
+100.0%
Q1 2018$4,600,000
-0.3%
964,306
+2.6%
0.01%0.0%
Q4 2017$4,613,000
-41.0%
939,473
-37.0%
0.01%
-50.0%
Q3 2017$7,820,000
-32.6%
1,492,317
-28.5%
0.01%
-36.8%
Q2 2017$11,609,000
-56.2%
2,088,007
-33.8%
0.02%
-59.6%
Q1 2017$26,491,000
+13.6%
3,153,628
-14.4%
0.05%
+17.5%
Q4 2016$23,315,000
+44.3%
3,683,151
+0.5%
0.04%
+37.9%
Q3 2016$16,162,000
+65.7%
3,664,867
+6.7%
0.03%
+61.1%
Q2 2016$9,752,000
-15.0%
3,433,652
-15.3%
0.02%
-14.3%
Q1 2016$11,475,000
-56.7%
4,055,066
+58.0%
0.02%
-46.2%
Q4 2015$26,494,000
-6.0%
2,567,215
+3.8%
0.04%
-7.1%
Q3 2015$28,192,000
-12.9%
2,472,974
+14.1%
0.04%
-12.5%
Q2 2015$32,372,000
+107.9%
2,168,252
+25.8%
0.05%
+100.0%
Q1 2015$15,569,000
-23.4%
1,724,137
+3.2%
0.02%
-7.7%
Q4 2014$20,313,000
-0.7%
1,670,539
-20.2%
0.03%
-3.7%
Q3 2014$20,464,000
-33.7%
2,092,361
-13.6%
0.03%
-35.7%
Q2 2014$30,883,000
+41.1%
2,422,218
+17.1%
0.04%
+35.5%
Q1 2014$21,891,000
+18.0%
2,069,060
-15.2%
0.03%
+24.0%
Q4 2013$18,545,000
+209.7%
2,440,177
+196.7%
0.02%
+150.0%
Q3 2013$5,988,000
+5107.0%
822,508
+1004.8%
0.01%
Q2 2013$115,00074,4500.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Burrage Capital Management LLC 1,105,673$8,237,0006.28%
Sarissa Capital Management LP 8,175,000$60,903,0006.22%
ORACLE INVESTMENT MANAGEMENT INC 2,980,870$22,207,0002.78%
DG Capital Management, LLC 1,075,732$8,014,0001.70%
Ghost Tree Capital, LLC 900,000$6,705,0001.49%
Parkman Healthcare Partners LLC 538,370$4,011,0001.03%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,835,810$43,477,0000.86%
Formidable Asset Management, LLC 470,419$3,470,0000.80%
KNOTT DAVID M 219,461$1,635,0000.74%
Altium Capital Management LP 250,000$1,863,0000.70%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders